Faculty Affiliates

Zev Schuman-Olivier, MD

Director, Center for Mindfulness and Compassion; Director of Addiction Research, Cambridge Health Alliance; Assistant Professor in Psychiatry, Harvard Medical School

Addiction & Mental Illness; Clinical Treatment; Meditation


Contact

Zev Schuman-Olivier, MD
Director, Center for Mindfulness and Compassion; Director of Addiction Research, Cambridge Health Alliance; Assistant Professor in Psychiatry, Harvard Medical School

zschuman@cha.harvard.edu


Selected Publications
  • Schuman-Olivier Z, Hoeppner BB, Evins AE, Brewer JA. Finding the right match: mindfulness training may potentiate the therapeutic effect of nonjudgment of inner experience on smoking cessation. Subst Use Misuse. 2014 Apr;49(5):586-94. doi: 10.3109/10826084.2014.850254. PMID: 24611853; PMCID: PMC4096689.
  • Schuman-Olivier Z, Connery H, Griffin ML, Wyatt SA, Wartenberg AA, Borodovsky J, Renner JA Jr, Weiss RD. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013 Nov-Dec;22(6):574-80. doi: 10.1111/j.1521-0391.2013.12024.x. PMID: 24131165; PMCID: PMC3801272.
  • Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ. Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes. Drug Alcohol Depend. 2013 Oct 1;132(3):580-6. doi: 10.1016/j.drugalcdep.2013.04.006. PMID: 23688843; PMCID: PMC3916951.
  • Schuman-Olivier Z, Noordsy D, Brunette M. Strategies for reducing antipsychotic polypharmacy. Journal of Dual Diagnosis. 2013 May 3; 9(2): p. 208-218. doi: 10.1080/15504263.2013.778767.
  • Hölzel BK, Lazar SW, Gard T, Schuman-Olivier Z, Vago DR, Ott U. How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective. Perspect Psychol Sci. 2011 Nov;6(6):537-59. doi: 10.1177/1745691611419671. PMID: 26168376.
  • Schuman-Olivier Z, Albanese M, Nelson SE, Roland L, Puopolo F, Klinker L, Shaffer HJ. Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat. 2010 Jul;39(1):41-50. doi: 10.1016/j.jsat.2010.03.014. PMID: 20434868.
  • Schuman-Olivier, Z. Considering buprenorphine diversion in 2010. Brown University Digest of Addiction Theory and Application. 2010, 29(11): 8.
  • Schuman-Olivier Z, Brendel DH, Forstein M, Price BH. The use of palliative sedation for existential distress: A psychiatric perspective. Harv Rev Psychiatry. 2008;16(6):339-51. doi: 10.1080/10673220802576917. PMID: 19085388.
  • Margolin A, Schuman-Olivier Z, Beitel M, Arnold RM, Fulwiler CE, Avants SK. A preliminary study of spiritual self-schema (3-S(+)) therapy for reducing impulsivity in HIV-positive drug users. J Clin Psychol. 2007 Oct;63(10):979-99. doi: 10.1002/jclp.20407. PMID: 17828761.
  • Beitel M, Genova M, Schuman-Olivier Z, Arnold R, Avants SK, Margolin A. Reflections by inner-city drug users on a Buddhist-based spirituality-focused therapy: a qualitative study. Am J Orthopsychiatry. 2007 Jan;77(1):1-9. doi: 10.1037/0002-9432.77.1.1. PMID: 17352579.
  • Margolin A, Beitel M, Schuman-Olivier Z, Avants SK. A controlled study of a spirituality-focused intervention for increasing motivation for HIV prevention among drug users. AIDS Educ Prev. 2006 Aug;18(4):311-22. doi: 10.1521/aeap.2006.18.4.311. PMID: 16961448.
  • Schuman ZD, Abrahm JL. Implementing institutional change: An institutional case study of palliative sedation. J Palliat Med. 2005 Jun;8(3):666-76. doi: 10.1089/jpm.2005.8.666. PMID: 15992211.